Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkac409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Tzu-Ning Tseng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicin…. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Tenofovir. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Ministry of Science and Technology, Chang Gung Memorial Hospital.
Abstract (Originalsprache)
Background
For patients with chronic hepatitis B (CHB), the optimal stopping criteria for entecavir or tenofovir disoproxil fumarate treatment remain unclear.
Methods
This study recruited CHB patients with levels of hepatitis B surface antigen (HBsAg) <100 IU/mL at the end of treatment (EOT) from Kaohsiung (n = 190) and Linkou (n = 188) Chang Gung Memorial Hospitals for use as development and validation groups, respectively.
Results
In the development group, 108 patients with HBsAg ≤40 IU/mL were used for analysis of predictors of HBV relapse and HBsAg loss. Multivariate analysis showed that age, nucleos(t)ide analogue (NA)-experienced status, baseline hepatitis B core-related antigen (HBcrAg) and HBsAg at EOT were associated independently with virological and clinical relapse. An HBsAg level of 20 IU/mL at EOT was the best cut-off value for minimizing HBV relapse. Patients with EOT HBsAg ≤20 IU/mL had lower virological and clinical relapse rates and higher HBsAg loss rates than those with EOT HBsAg 21–40 IU/mL and HBsAg 41–100 IU/mL in the development and validation groups. The virological and clinical relapse rates were very low (5-year rates: 6.5% and 0%, respectively) and HBsAg loss rate was very high (5-year rate: 81.7%) in patients with a combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg ≤20 IU/mL in the development group.
Conclusions
A combination of baseline HBcrAg ≤4 log U/mL and EOT HBsAg level ≤20 IU/mL might reduce the risk of HBV relapse and increase HBsAg loss rate, and might be helpful for off-NA follow-up strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- Division of Hepatogastroenterology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.
ORCID-Profile: Wen-Juei Jeng, Tsung-Hui Hu
Förderung
- Ministry of Science and Technology
- Chang Gung Memorial Hospital
Zitieren
APA
Tseng, T. N., Jeng, W. J., Hu, T. H., Wang, J. H., Hung, C. H., Lu, S. N., & Chen, C. H. (2023). Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkac409
Vancouver
Tseng TN, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, et al. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkac409
BibTeX
@article{Tseng2023,
author = {Tseng, Tzu-Ning and Jeng, Wen-Juei and Hu, Tsung-Hui and Wang, Jing-Houng and Hung, Chao-Hung and Lu, Sheng-Nan and Chen, Chien-Hung},
title = {Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkac409}
}
EUVIMED